LUMOSA THERAPEUTICS CO LTD Statistics
LUMOSA THERAPEUTICS CO LTD (6535) Stock Statistics & Valuation Metrics
Total Valuation
LUMOSA THERAPEUTICS CO LTD has a market cap or net worth of TWD 11.78B. The enterprise value is TWD 23.02B.
- Market Cap
- TWD 11.78B
- Enterprise Value
- TWD 23.02B
Share Statistics
LUMOSA THERAPEUTICS CO LTD has 167,840,820 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 167,840,820
- Owned by Insiders
- ―
- Owned by Institutions
- 1.81%
Financial Efficiency
LUMOSA THERAPEUTICS CO LTD’s return on equity (ROE) is -0.23 and return on invested capital (ROIC) is -21.85%.
- Return on Equity (ROE)
- -0.23
- Return on Assets (ROA)
- -0.21
- Return on Invested Capital (ROIC)
- -21.85%
- Return on Capital Employed (ROCE)
- -0.22
- Revenue Per Employee
- 995.31K
- Profits Per Employee
- -9.63M
- Employee Count
- 36
- Asset Turnover
- 0.02
- Inventory Turnover
- 0.14
Valuation Ratios
The current PE Ratio of LUMOSA THERAPEUTICS CO LTD is -31.66. LUMOSA THERAPEUTICS CO LTD’s PEG ratio is -0.68.
- PE Ratio
- -31.66
- PS Ratio
- 344.07
- PB Ratio
- 9.47
- Price to FCF
- -45.90
- Price to Operating Cash Flow
- -45.52
- PEG Ratio
- -0.68
Income Statement
In the last 12 months, LUMOSA THERAPEUTICS CO LTD had revenue of 35.83M and earned -346.62M in profits. Earnings per share was -2.05.
- Revenue
- 35.83M
- Gross Profit
- 21.87M
- Operating Income
- -333.49M
- Pretax Income
- -346.62M
- Net Income
- -346.62M
- EBITDA
- -322.23M
- Earnings Per Share (EPS)
- -2.05
Cash Flow
In the last 12 months, operating cash flow was -257.63M and capital expenditures 0, giving a free cash flow of -257.63M billion.
- Operating Cash Flow
- -257.63M
- Free Cash Flow
- -257.63M
- Free Cash Flow per Share
- -1.55
Dividends & Yields
LUMOSA THERAPEUTICS CO LTD pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -2.15%
- Earnings Yield
- -3.12%
Stock Price Statistics
- Beta
- 0.21
- 52-Week Price Change
- -65.92%
- 50-Day Moving Average
- 76.48
- 200-Day Moving Average
- 113.59
- Relative Strength Index (RSI)
- 40.54
- Average Volume (3m)
- 280.75K
Important Dates
LUMOSA THERAPEUTICS CO LTD upcoming earnings date is Mar 01, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 01, 2027
- Ex-Dividend Date
- ―
Financial Position
LUMOSA THERAPEUTICS CO LTD as a current ratio of 7.37, with Debt / Equity ratio of 0.46%
- Current Ratio
- 7.37
- Quick Ratio
- 6.62
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.54
- Interest Coverage Ratio
- -1659.15
Taxes
In the past 12 months, LUMOSA THERAPEUTICS CO LTD has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
LUMOSA THERAPEUTICS CO LTD EV to EBITDA ratio is -46.55, with an EV/FCF ratio of -46.01.
- EV to Sales
- 344.91
- EV to EBITDA
- -46.55
- EV to Free Cash Flow
- -46.01
- EV to Operating Cash Flow
- -46.01
Balance Sheet
LUMOSA THERAPEUTICS CO LTD has TWD 633.00M in cash and marketable securities with TWD 3.48M in debt, giving a net cash position of TWD 629.52M billion.
- Cash & Marketable Securities
- TWD 633.00M
- Total Debt
- TWD 3.48M
- Net Cash
- TWD 629.52M
- Net Cash Per Share
- TWD 3.75
- Tangible Book Value Per Share
- TWD 7.50
Margins
Gross margin is 53.09%, with operating margin of -882.81%, and net profit margin of -1076.78%.
- Gross Margin
- 53.09%
- Operating Margin
- -882.81%
- Pretax Margin
- -1091.93%
- Net Profit Margin
- -1076.78%
- EBITDA Margin
- -740.89%
- EBIT Margin
- -771.57%
Analyst Forecast
The average price target for LUMOSA THERAPEUTICS CO LTD is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -7.74%
- EPS Growth Forecast
- 41.63%
